Cours Daiichi Sankyo Company, Limited Other OTC
Actions
DSNKY
US23381D1028
Produits pharmaceutiques
CA 2024 | 1 602 Md 10,11 Md 9,24 Md | CA 2025 * | 1 761 Md 11,12 Md 10,16 Md | Capitalisation | 9 607 Md 60,65 Md 55,42 Md |
---|---|---|---|---|---|
Résultat net 2024 | 201 Md 1,27 Md 1,16 Md | Résultat net 2025 * | 186 Md 1,17 Md 1,07 Md | VE / CA 2024 | 5,72 x |
Trésorerie nette 2024 * | 556 Md 3,51 Md 3,21 Md | Trésorerie nette 2025 * | 455 Md 2,87 Md 2,62 Md | VE / CA 2025 * | 5,2 x |
PER 2024 |
45,6
x | PER 2025 * |
49
x | Employés | - |
Rendement 2024 |
1,05% | Rendement 2025 * |
1,14% | Flottant | 97,04% |
Dernier transcript sur Daiichi Sankyo Company, Limited
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/04/07 |
Hiroyuki Okuzawa
PSD | President | 61 | 01/04/17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 01/06/19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 01/06/19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/04/07 |
Varia. 1 janv. | Capi. | |
---|---|---|
+25,83% | 661 Md | |
+27,00% | 566 Md | |
-6,76% | 352 Md | |
+20,34% | 332 Md | |
+3,00% | 283 Md | |
+13,09% | 231 Md | |
+5,46% | 200 Md | |
-9,61% | 195 Md | |
-6,26% | 145 Md |